Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Nov;132(5):509-12.

Emergence of drug resistant mutations after single dose nevirapine exposure in HIV-1 infected pregnant women in south India

Lakshmi Rajesh  1 , K Ramesh, Luke Elizabeth Hanna, P R Narayanan, Soumya Swaminathan
Affiliations

Emergence of drug resistant mutations after single dose nevirapine exposure in HIV-1 infected pregnant women in south India

Lakshmi Rajesh et al. Indian J Med Res. 2010 Nov.

Abstract

Background & objectives: Resistance to nevirapine (NVP) has been described with single dose preventive regimens in other populations. Our aim was to study the pattern and prevalence of HIV drug resistance (DR) at baseline (during pregnancy) and after delivery among antenatal women exposed to single dose NVP for prevention of parent to child transmission (PPTCT).

Methods: HIV-infected, ART-naive primigravidae between 18-25 years of age, attending government antenatal clinics in Chennai, Vellore or Madurai were recruited. Drug resistance testing was carried out during pregnancy and after Sd-NVP treatment (one month after delivery) by Viroseq sequencing. HIV-1 testing by DNA PCR was done in newborns at 30 days.

Results: Thirty one women were enrolled but only twenty six plasma specimens were analyzable (24 paired and two postnatal only). No major mutations were observed in any drug class at baseline though many polymorphisms were observed in both the reverse transcriptase and protease genes. Mutations to non-nucleoside reverse transcriptase inhibitors (NNRTI) were observed post-delivery in 33 per cent of women who were treated with Sd-NVP. None of the infants were HIV-positive.

Interpretation & conclusions: Among pregnant ART-naive women, baseline HIV drug resistance was not observed. A high rate of development of NNRTI class resistance among women treated with single-dose NVP was observed. Our results emphasize the need to implement more effective PPTCT regimens, minimizing emergence of drug resistance and thereby preserving long-term treatment options for HIV-infected women in India.

PubMed Disclaimer

References

    1. UNAIDS WHO. HIV/AIDS Epidemic update. Epidemiological fact sheet on HIV/AIDS, India- WHO/UNAIDS. 2008 update131. 2007 Available at: http://www.unaids.org/en/KnowledgeCentre/HIVData/EpiUpdate/EpiUpdArchive... accessed on December 22, 2008.
    1. NACO. Guidelines for HIV care and treatment in infants and children. 2006 Available at: http://www.nacoonline.org/Quick_Links/Publication/Treatment_Care__Suppor..., accessed o December 22, 2008.
    1. Giaquinto C, Rampon O, de Rossi A. Antiretroviral therapy for prevention of mother to child transmission. Clin Drug Invest. 2006;26:611–27. - PubMed
    1. Rapid Advice, WHO guidelines. Geneva: WHO; 2009. Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants.
    1. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanuwong C, Kantipong P, Leechanachai P, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med. 2004;351:229–40. - PubMed

Publication types